The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2 (Small 39/2024)
COVID-19 Antiviral The global need for next generation antivirals due to SARS-CoV-2 mutations led to interest in niclosamide, a broad spectrum antiviral. XAFTY is a niclosamide-inorganic nanohybrid drug proven for its broad-spectrum antiviral activity, overcoming niclosamide's low bioavailability. It has been confirmed in animal models to reduce SARS-CoV-2 viral load and prevent infection-induced lung inflammation, and its safety was confirmed in the clinical trials. More in article number 2305148, Geun-woo Jin, Jin-Ho Choy, and co-workers.
Authors
- Jin‐Ho Choy (ORCID: https://orcid.org/0000-0002-4149-7100)
- Huiyan Piao (ORCID: https://orcid.org/0000-0001-9998-3411)
- Young Bae Ryu (ORCID: https://orcid.org/0000-0002-2683-7066)
- Jeong In Seo (ORCID: https://orcid.org/0000-0003-0365-925X)
- Hyung‐Jun Kwon (ORCID: https://orcid.org/0000-0002-6429-8075)
- N. Sanoj Rejinold (ORCID: https://orcid.org/0000-0002-7045-0563)
- Hye Hyun Yoo (ORCID: https://orcid.org/0000-0001-8282-852X)
- Geun‐woo Jin (ORCID: https://orcid.org/0000-0002-5561-1103)
- Goeun Choi (ORCID: https://orcid.org/0000-0002-5424-8322)
- In Chul Lee
Institutions
- Tokyo Institute of Technology (JP)
- Hanyang University (KR)
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Dankook University (KR)
Publication Details
- Journal
- Small
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/smll.202470291
- Primary Topic
- Advanced Nanomaterials in Catalysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00